Actinium Announces Iomab-B Markedly Increases Long-term Survival In Older Patients With Active Relapsed/Refractory Acute Myeloid Leukemia In Phase 3 SIERRA Trial At 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings Of ASTCT And CIBMTR
Portfolio Pulse from Benzinga Newsdesk
Actinium Pharmaceuticals announced that its Iomab-B treatment significantly improves long-term survival rates in older patients with active relapsed/refractory acute myeloid leukemia, according to Phase 3 SIERRA trial results presented at the 2024 Tandem Meetings of ASTCT and CIBMTR.
February 26, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Actinium Pharmaceuticals' announcement of positive Phase 3 trial results for Iomab-B could significantly boost investor confidence and potentially lead to an increase in stock price.
Positive clinical trial results, especially from a Phase 3 trial, are critical for biotech companies like Actinium Pharmaceuticals. Such results not only validate the efficacy of the treatment but also bring the company closer to potential FDA approval and commercialization. This can lead to increased investor confidence, potentially driving up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100